Facebook
Twitter
Telegram
Report an ErrorVYNE Therapeutics Balance Sheet 2011-2024 | VYNE
Annual Balance Sheet VYNE Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -22.8 M | -30.8 M | -49.5 M | -10.2 M | -4.03 M | -43.8 M | - | - | - | - | ||
Long Term Debt |
- | - | - | 33.2 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
115 K | - | 349 K | 757 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.41 M | - | - | 34.8 M | - | 7 K | 116 M | 67.6 M | 59.1 M | - | - | - | - |
Total Current Liabilities |
7.54 M | 9.34 M | - | 21.5 M | 10.7 M | 9.54 M | 7.82 M | - | - | - | - | - | - |
Total Liabilities |
8.95 M | 9.34 M | 18.4 M | 56.2 M | 10.7 M | 9.55 M | 124 M | 71.5 M | 59.8 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 1.8 M | 1.8 M | - | - | - | - | - |
Retained Earnings |
-691 M | -663 M | -640 M | -566 M | - | -111 M | -59.2 M | -30.1 M | -16 M | - | - | - | - |
Total Assets |
97.7 M | 40.8 M | 67 M | 93.7 M | 79.2 M | 140 M | 66.9 M | 42.1 M | 43.9 M | - | - | - | - |
Cash and Cash Equivalents |
30.6 M | 30.9 M | 42.2 M | 57.6 M | 30.8 M | 49.5 M | 10.2 M | 4.03 M | 43.8 M | - | - | - | - |
Book Value |
88.7 M | 31.4 M | 48.6 M | 37.5 M | 68.5 M | 130 M | -57 M | -29.4 M | -16 M | - | - | - | - |
Total Shareholders Equity |
88.7 M | 31.2 M | 48.6 M | 37.5 M | 17.6 M | 130 M | -57 M | -29.4 M | -16 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet VYNE Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | 33.3 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | 34.5 M | 35 M | 35.1 M | 34.4 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
7.76 M | 7.69 M | 8.83 M | 9.34 M | 6.84 M | 6.84 M | 8.59 M | 18.4 M | 22.4 M | 59.1 M | 56.3 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 9.55 M | 9.55 M | 9.55 M | 9.55 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-685 M | -679 M | -669 M | -663 M | -653 M | -643 M | -635 M | -640 M | -628 M | -607 M | -587 M | -566 M | -566 M | -566 M | -566 M | -311 M | -311 M | -311 M | -311 M | -111 M | -111 M | -111 M | -111 M | -59.2 M | -59.2 M | -59.2 M | -59.2 M | -30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
19.3 M | 25 M | 35.3 M | 40.8 M | 46.9 M | 55.2 M | 64.3 M | 67 M | 81.3 M | 134 M | 149 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 81.2 M | 81.2 M | 81.2 M | 81.2 M | 140 M | 140 M | 140 M | 140 M | 66.9 M | 66.9 M | 66.9 M | 66.9 M | 42.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
15.4 M | 20.6 M | 30.2 M | 30.9 M | 35.5 M | 42.8 M | 50.5 M | 42.2 M | 52.3 M | 103 M | 119 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 27.9 M | 49.5 M | 49.5 M | 49.5 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 4.03 M | - | - | - | 43.8 M | - | - | - | 273 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
11.5 M | 17.3 M | 26.4 M | 31.4 M | 40.1 M | 48.4 M | 55.7 M | 48.6 M | 58.9 M | 74.9 M | 92.9 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 130 M | 130 M | 130 M | 130 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
11.5 M | 17.3 M | 26.4 M | 31.2 M | 40.1 M | 48.4 M | 55.7 M | 48.6 M | 58.9 M | 74.9 M | 92.9 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 92.2 M | 130 M | 130 M | 130 M | 68.6 M | -57 M | -57 M | -57 M | -29.4 M | - | - | - | -16 M | - | - | - | -11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency